Abstract
This study presents a novel reverse-engineering approach to generate recombinant anti-PF4 antibodies from VITT-patient sera. These antibodies recapitulate functional effects of original serum anti-PF4 clonotypes, identify key PF4 binding residues and hold promise as valuable tools to investigate VITT etiology.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
